Endogenous nitric oxide contributes to bradykinin-stimulated glucose uptake but attenuates vascular tissue-type plasminogen activator release

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 1, 2010, Pages 291-297

  Pretorius, Mias ^a   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BRADYKININ; CHOLESTEROL; GLUCOSE; ISOSORBIDE DINITRATE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SILDENAFIL; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BODY MASS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; FIBRINOLYSIS; FOREARM BLOOD FLOW; GENDER; GLUCOSE TRANSPORT; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; VASCULAR RESISTANCE; VASCULAR TISSUE; VASODILATATION;

ADULT; ASPIRIN; BRADYKININ; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; FOREARM; GLUCOSE; HUMANS; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; OBESITY; OMEGA-N-METHYLARGININE; REGIONAL BLOOD FLOW; TISSUE PLASMINOGEN ACTIVATOR; VASODILATION;

EID: 73949123406     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160168     Document Type: Article

References (33)

1. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, and Gingell C (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47-52.
2. Brown NJ, Gainer JV, Murphey LJ, and Vaughan DE (2000) Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase- independent pathway. Circulation 102:2190-2196.
3. Brown NJ, Gainer JV, Stein CM, and Vaughan DE (1999) Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 33: 1431-1435.
4. Brown NJ and Vaughan DE (1998) Angiotensin-converting enzyme inhibitors. Circulation 97:1411-1420.
5. Chia S, Qadan M, Newton R, Ludlam CA, Fox KA, and Newby DE (2003) Intraarterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 23:695-701.
6. Daniel VC, Minton TA, Brown NJ, Nadeau JH, and Morrow JD (1994) Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 653:117-122.
7. Emeis JJ, van den Eijnden-Schrauwen Y, and Kooistra T (1996) Tissue-type plasminogen activator and the vessel wall: Synthesis, storage and secretion., in Vascular Control of Hemostasis (van Hinsbergh VWM ed) pp 187-206, Harwood Academic Publishers.
8. Giannarelli C, De Negri F, Virdis A, Ghiadoni L, Cipriano A, Magagna A, Taddei S, and Salvetti A (2007) Nitric oxide modulates tissue plasminogen activator release in normotensive subjects and hypertensive patients. Hypertension 49:878-884.
9. Hokanson DE, Sumner DS, and Strandness DE Jr (1975) An electrically calibrated plethysmograph for direct measurement of limb blood flow). IEEE Trans Biomed Eng 22:25-29.
10. Hrafnkelsdóttir T, Wall U, Jern C, and Jern S (1998) Impaired capacity for endogenous fibrinolysis in essential hypertension. Lancet 352:1597-1598.
11. Iafrati MD, Vitseva O, Tanriverdi K, Blair P, Rex S, Chakrabarti S, Varghese S, and Freedman JE (2005) Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. Am J Physiol Heart Circ Physiol 288:H1627-H1632.
12. Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, and Webb DJ (2001) Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol 38:1402-1408.
13. Laine H, Yki-Jarvinen H, Kirvela O, Tolvanen T, Raitakari M, Solin O, Haaparanta M, Knuuti J, and Nuutila P (1998) Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J Clin Invest 101:1156-1162.
14. Leeson P, Thorne S, Donald A, Mullen M, Clarkson P, and Deanfield J (1997) Non-invasive measurement of endothelial function: effect on brachial artery dilatation of graded endothelial dependent and independent stimuli. Heart 78:22-27.
15. Matsushita K, Morrell CN, Cambien B, Yang SX, Yamakuchi M, Bao C, Hara MR, Quick RA, Cao W, O'Rourke B, et al. (2003) Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell 115:139-150.
16. Muldowney JA 3rd, Painter CA, Sanders-Bush E, Brown NJ, and Vaughan DE (2007) Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6- epoxyeicosatrienoic acid. Thromb Haemost 97:263-271.
17. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA, and Boon NA (2001) Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 103:1936-1941.
18. Nichols DJ, Muirhead GJ, and Harness JA (2002). Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 53 Suppl 1:5S-12S.
19. Nuutila P, Raitakari M, Laine H, Kirvelä O, Takala T, Utriainen T, Mäkimattila S, Pitkänen OP, Ruotsalainen U, Iida H, et al. (1996) Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission tomography. J Clin Invest 97:1741-1747.
20. Parmer RJ and Miles LA (1998) Targeting of tissue plasminogen activator to the regulated pathway of secretion. Trends Cardiovasc Med 8:306-312.
21. Pretorius M, Luther JM, Murphey LJ, Vaughan DE, and Brown NJ (2005) Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. Arterioscler Thromb Vasc Biol 25:2435-2440.
22. Pretorius M, Rosenbaum D, Vaughan DE, and Brown NJ (2003) Angiotensinconverting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 107:579-585.
23. Pretorius M, van Guilder GP, Guzman RJ, Luther JM, and Brown NJ (2008) 17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women. Hypertension 51:1190-1196.
24. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, and Hennekens CH (1992) Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 85:1822-1827.
25. Robinson SD, Ludlam CA, Boon NA, and Newby DE (2007) Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 27:1651-1656.
26. Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, and Horiuchi M (2002) ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 40:329-334.
27. Shiuchi T, Nakagami H, Iwai M, Takeda Y, Cui T, Chen R, Minokoshi Y, and Horiuchi M (2001) Involvement of bradykinin and nitric oxide in leptin-mediated glucose uptake in skeletal muscle. Endocrinology 142:608-612.
28. Smith DT, Hoetzer GL, Greiner JJ, Stauffer BL, and DeSouza CA (2003) Endothelial release of tissue-type plasminogen activator in the human forearm: role of nitric oxide. J Cardiovasc Pharmacol 42:311-314.
29. Tranquille N and Emeis JJ (1993) The role of cyclic nucleotides in the release of tissue-type plasminogen activator and von Willebrand factor. Thromb Haemost 69:259-261.
30. Ueda S, Wada A, and Umemura S (2004) Methodological validity and feasibility of the nitric oxide clamp technique for nitric oxide research in human resistant vessels. Hypertens Res 27:351-357.
31. van den Eijnden-Schrauwen Y, Kooistra T, de Vries RE, and Emeis JJ (1995) Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. Blood 85:3510-3517.
32. Van Guilder GP, Hoetzer GL, Smith DT, Irmiger HM, Greiner JJ, Stauffer BL, and DeSouza CA (2005) Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise. Am J Physiol Endocrinol Metab 289:E807-E813.
33. Van Guilder GP, Stauffer BL, Greiner JJ, and DeSouza CA (2008) Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists. Am J Physiol Heart Circ Physiol 294: H1685-H1692.